Drug intelligence / Profile preview

MK-4464

Development stage: Phase 1
Lead developer: Merck
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MK-4464 is an investigational antibody-based trifunctional molecule (TriNKET) designed for cancer immunotherapy. It recruits immune cells into tumors and directly activates the killing of cancer cells by binding to CEACAM5 on cancer cells and NKG2D and CD16A on natural killer (NK) cells, as well as engaging cytotoxic T cells. The drug is being studied for the treatment of advanced or metastatic solid tumors, both as monotherapy and in combination with pembrolizumab. Its dual mechanism aims to enhance immune cell infiltration into tumors and promote direct tumor cell lysis[1][5][4].

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)NKG2D (Natural killer group 2 member D receptor)

Beyond the preview

Go deeper on MK-4464.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-4464.

Explore the full profile